{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-026761","form_type":"8-K","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.613390+00:00","generated_at":"2026-06-18T22:05:08.550402+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"VYNE extends Oral BETi option to April 30, 2023; regains Nasdaq minimum bid price compliance","bullets":["Extended option term for Oral BETi Compounds to April 30, 2023; paid Tay $250k non-refundable fee.","Fee will be deducted from $4.0M upfront if option exercised.","Received Nasdaq notice on Feb 28, 2023 that bid price ≥$1.00 for 10 consecutive business days through Feb 27, 2023.","Regained compliance with Nasdaq Rule 5550(a)(2)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-026761","json":"https://secwatch.observer/filing/0001104659-23-026761.json","markdown":"https://secwatch.observer/filing/0001104659-23-026761.md","text":"https://secwatch.observer/filing/0001104659-23-026761.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000110465923026761/0001104659-23-026761-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000110465923026761/tm237985d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T22:05:08.550402+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ae6135e03dd9f1f42fdd3438cf4c8675761ca867","claim":"VYNE Therapeutics Inc. amended Letter Agreement with Tay Therapeutics Limited valued at $250,000 (effective 2023-02-27).","evidence_excerpt":"the parties entered into a Letter Agreement on February 27, 2023 (the “Letter Agreement”) to extend the Option Term to April 30, 2023. Pursuant to the terms of the Letter Agreement, VYNE has agreed to pay Tay a non-refundable fee in the amount of $250,000 to extend the Option Term.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465923026761/0001104659-23-026761-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Tay Therapeutics Limited"},{"label":"Value","value":"$250,000"},{"label":"Effective","value":"2023-02-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}